2. Academic Validation
  3. Discovery of a tau-aggregate clearing compound that covalently targets P4HB

Discovery of a tau-aggregate clearing compound that covalently targets P4HB

  • Cell Chem Biol. 2025 Oct 16;32(10):1235-1248.e34. doi: 10.1016/j.chembiol.2025.09.006.
Louis P Conway 1,  Michelle A Estrada 2,  Weichao Li 1,  Stephen Walker 3,  Benjamin Mielich-Süss 4,  Anurupa Shrestha 2,  Matthew Townsend 5,  Jürgen Korffmann 4,  Greg Potts 2,  Janice Lee 2,  Kenneth P Robinson 2,  Shiyao Wang 2,  Brian Bierie 2,  John R Koenig 2,  Phil Cox 2,  Paul Richardson 2,  Manisha Jhala 3,  Becca McCloud 2,  Sujatha Gopalakrishnan 3,  Kevin Woller 2,  Anil Vasudevan 2,  Scott E Warder 2,  Shaun M McLoughlin 6,  Christopher G Parker 7
Affiliations

Affiliations

  • 1 Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • 2 Technology and Therapeutic Platforms, AbbVie, 1 N. Waukegan Rd., North Chicago, IL 60064, USA.
  • 3 Target Enabling Technologies, AbbVie, 1 N. Waukegan Rd., North Chicago, IL 60064, USA.
  • 4 Discovery Biology, AbbVie GmbH, Knollstrasse, 67061 Ludwigshafen, Rhineland-Palatinate, Germany.
  • 5 Discovery Neuroscience Research, AbbVie Cambridge Research Center, 200 Sidney St., Cambridge, MA 02139, USA.
  • 6 Technology and Therapeutic Platforms, AbbVie, 1 N. Waukegan Rd., North Chicago, IL 60064, USA. Electronic address: shaun.mcloughlin@abbvie.com.
  • 7 Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: cparker@scripps.edu.
PMID: 41056949 DOI: 10.1016/j.chembiol.2025.09.006
Abstract

The improper folding and aggregation of tau are linked to several neurodegenerative diseases affecting millions worldwide. However, the pathogenesis of tauopathies remains poorly understood, resulting in limited effective treatments. Here, we employ an integrated chemoproteomic phenotypic strategy to identify druggable targets and corresponding chemical probes for the treatment of tauopathies. We identified and optimized an indole-amine compound that potently and extensively clears tau aggregates in two human tauopathy models. Mechanistic and chemoproteomic studies implicate protein disulfide isomerase 1 (P4HB) as the primary target, forming covalent adducts upon metabolic activation. Knockdown of P4HB reduced tau aggregates in three tauopathy models, including an ex vivo murine neuron preclinical model. Functional characterization revealed the compound induces mild endoplasmic reticulum (ER)-stress responses as assessed by RNA Sequencing and whole proteomic profiling. Our findings highlight P4HB as a potential therapeutic target for treatment of tauopathies.

Keywords

chemoproteomics; neurodegenerative disease; phenotypic screening; target identification; tauopathy.

Figures
Products